Similar articles

• [Chemotherapy for ovarian cancer--introduction].

  Yamada H, Sugiyama T. Yamada H, et al. Nihon Rinsho. 2004 Oct;62 Suppl 10:540-5. Nihon Rinsho. 2004. PMID: 15535304 Review. Japanese. No abstract available.
• [Ovarian cancer treatment from the standpoint of the gynecologic oncologist].

  Sugiyama T, Yoshizaki A, Hatayama S. Sugiyama T, et al. Gan To Kagaku Ryoho. 2007 Jul;34(7):1011-6. Gan To Kagaku Ryoho. 2007. PMID: 17637537 Japanese.
• Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.

  Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Greimel ER, et al. J Clin Oncol. 2006 Feb 1;24(4):579-86. doi: 10.1200/JCO.2005.02.4067. J Clin Oncol. 2006. PMID: 16446330 Clinical Trial.
• Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.

  Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A, Young RC. Ozols RF, et al. Gynecol Oncol. 2006 Oct;103(1):1-6. doi: 10.1016/j.ygyno.2006.06.026. Epub 2006 Aug 10. Gynecol Oncol. 2006. PMID: 16904166 No abstract available.
• [Therapy for ovarian cancer--general review].

  Ochiai K. Ochiai K. Nihon Rinsho. 2004 Oct;62 Suppl 10:517-21. Nihon Rinsho. 2004. PMID: 15535299 Review. Japanese. No abstract available.